Angitia Biopharmaceuticals Presents First-in-Human Data on AGA2118 for Osteoporosis at ASBMR 2024

Abstracts selected for 2 oral presentations and 2 poster presentations, including clinical and preclinical data sets

WOODLAND HILLS, California, USA, May 16, 2024 – Angitia Biopharmaceuticals, a global, clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced positive top-line results from its first in human (FIH) study of AGA2118. The study, entitled “A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability, Absolute Bioavailability, Pharmacokinetics, and Pharmacodynamics of AGA2118 in Men and Postmenopausal Women”, demonstrates an excellent safety and tolerability profile, as well as preliminary efficacy in increasing bone mineral density (BMD) after single and multiple dose administrations.